---
title: relapse refractory of treatment of acute lymphoblastic leukemia (ALL)
date: "2023-01-22"
enableToc: false
---

> [!info]
>
> ğŸŒ± ä¾†è‡ª: [[treatment of acute lymphoblastic leukemia (ALL)]]

# relapse refractory of treatment of acute lymphoblastic leukemia (ALL)

*   salvage therapy
	* FLAG ï¼ˆfludarabine + cytarabine + G-CSF)
	* mitoxantrone åˆä½µcytarabineã€
	* é«˜åŠ‘é‡ cytarabineï¼ˆ3 g/m2 Q12Hï¼‰

> å¤šæ•¸ç—…äººå°ç¬¬äºŒç·šåŒ–ç™‚çš„åæ‡‰ä¸ä½³ã€‚

*   then ğŸ‘‰ allogeneic HSCT

### B cell:Â 

*   [[blinatumomab]] ğŸ¦·bli-na-**TU**-mo-mab
    *   (CD19 BiTE-bispecific T-cell engager;Â NEJM2017;376:836)
*   [[inotuzumab]] ğŸ·ino-**TU**-zu-mab
    *   (CD22 Ab drug conjugate;Â NEJM2016;375:740)
*   tisagenlecleucel and brexucabtagene autoleucel
    *   (CD19 CAR-T,Â NEJMÂ 2018;378:449;Â LancetÂ 2021;398:491)
*   TKI+chemo/steroids (Ph âŠ•t(9;22) only)

### T cell

*   nelarabine
*   Â± cyclophosphamide
*   etoposide

### Both B & T cell:Â 

*   chemo including
*   : high dose cytarabine regimens;
*   : clofarabine
